
    
      104 treatment-na√Øve patients with HBeAg-positive chronic hepatitis B who fulfill the
      inclusion criteria will be randomized in a 1:1 ratio to receive either Telbivudine 600mg
      monotherapy or Entecavir monotherapy with stratification before randomization according to
      presence of cirrhosis. For Telbivudine group, Telbivudine monotherapy or Tenofovir combined
      therapy will be done according to virologic response at 24 weeks and the primary study will
      be completed at Week 48 and treatment response will be analyzed. The treatment will be
      extended to Week 96 and the secondary analysis will be performed then.
    
  